
    
      The MTD was found in the phase I portion of this study to be oral lapatinib 1000 mg per day
      for each 4 week cycle and paclitaxel 60 mg/m2 weekly x 3 of a 4 week cycle and carboplatin
      AUC 2 weekly x 3 of a 4 week cycle.
    
  